Study of VX-985 in Subjects With Chronic Hepatitis C

Phase 1 Completed 21 enrolled Vertex Pharmaceuticals Incorporated

RandomizedSingle-groupQuadruple-blindTreatment

Summary

The purpose of this study it to evaluate the safety and tolerability of VX-985 in HCV subjects. This study will also evaluate the antiviral activity and pharmacokinetic profile of VX-985.

Timeline

Start: 2010-06
Primary completion: 2010-10
Completion: 2010-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VX-985	Unknown	—	—

Study of VX-985 in Subjects With Chronic Hepatitis C

Summary

Timeline

Drugs

Indications